A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Authors:
  • JMJoseph Markowitz
    Joseph Markowitz
  • NPNichole Prescott
    Nichole Prescott
  • WSWolfgang Sadee
    Wolfgang Sadee
  • NHNyla Heerema
    Nyla Heerema
  • LWLai Wei
    Lai Wei
  • ZDZunyan Dai
    Zunyan Dai
  • APAudrey Papp
    Audrey Papp
  • ACAngela Campbell
    Angela Campbell
  • KCKristy Culler
    Kristy Culler
  • CBCatherine Balint
    Catherine Balint
  • BOBert O'Neil
    Bert O'Neil

Abstract
Background: Hepatocellular carcinoma (HCC) is on the rise worldwide. HCC responds poorly to chemotherapy. Lapatinib is an inhibitor of epidermal growth factor receptor and HER2/NEU both implicated in hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in HCC. Methods: A Fleming phase II design with a single stage of 25 patients with a 90% power to exclude a true response rate of 120 days. Median progression-free survival was 1.9 months and median overall survival was 12.6 months. Patients who developed a rash had a borderline statistically significant longer survival. Tissue and blood specimens were available on >90% of patients. No somatic mutations in EGFR (exons 18-21) were found. In contrast to our previous findings, we did not find evidence of HER2/NEU somatic mutations. PTEN, P-AKT, and P70S6K expression did not correlate with survival. Conclusions: Lapatinib is well-tolerated but seems to benefit only a subgroup of patients for whom predictive molecular or clinical characteristics are not yet fully defined. (Clin Cancer Res 2009;15(18):5895–901)

This publication has 50 references indexed in Scilit: